Although the results of the present study are preliminary, GH responsiveness of patients with both FM and severe obesity should be carefully evaluated, since GH replacement therapy might potentially improve the clinical symptoms and the general well-being of those with GHD [5, 20]. Here, GH1 is linked to obesity due to melanocortin 4 receptor deficiency.